Roche's Genentech defends supply shift for top cancer drugs

November 24, 2014 11:41 PM

14 0

(Reuters) - Genentech, U.S. biotech unit of Roche Holding, faces growing pressure over a decision to allow only a handful of distributors to supply three of the world's most widely used cancer drugs, a move that prominent hospitals say will create delays and raise costs.

Genentech in October began distributing Avastin, Herceptin and Rituxan to hospitals and clinics through six specialty drug distributors, rather than through drug wholesalers, which distribute a wide range of medicines, devices and equipment on an enormous scale. Specialty distributors supply biologi...

Read more

To category page